Abstract
Drug development for neurodegenerative diseases such as Alzheimer’s disease (AD) is a challenge, not only due to the cellular molecular mechanisms involved, but also because of the inherent difficulty of most molecules to cross the blood-brain-barrier (BBB). A promising approach to overcome these drawbacks is developing fluorinated molecules and supramolecular assemblies.
This review focuses on the therapeutic potential of new fluorinated molecules, developed as active and selective agents for AD, to meet the desired pharmacokinetic/pharmacodynamic properties and BBB targeting. The methods to fluorinate organic molecules and a brief characterization of the mechanisms of AD progression and therapeutic approaches are described.
The paradigm of cell biology knowledge and fluorine biochemistry such as, organofluorine inhibitors of amyloid fibrilogenesis, is highlighted.
Keywords: Fluorine, Alzheimer’s disease, therapeutic drugs, beta amyloid, aggregation mechanism.
Current Pharmaceutical Design
Title:The Potential Effect of Fluorinated Compounds in the Treatment of Alzheimer’s Disease
Volume: 21 Issue: 39
Author(s): Barbara Gomes, Joana A. Loureiro, Manuel A.N. Coelho and Maria do Carmo Pereira
Affiliation:
Keywords: Fluorine, Alzheimer’s disease, therapeutic drugs, beta amyloid, aggregation mechanism.
Abstract: Drug development for neurodegenerative diseases such as Alzheimer’s disease (AD) is a challenge, not only due to the cellular molecular mechanisms involved, but also because of the inherent difficulty of most molecules to cross the blood-brain-barrier (BBB). A promising approach to overcome these drawbacks is developing fluorinated molecules and supramolecular assemblies.
This review focuses on the therapeutic potential of new fluorinated molecules, developed as active and selective agents for AD, to meet the desired pharmacokinetic/pharmacodynamic properties and BBB targeting. The methods to fluorinate organic molecules and a brief characterization of the mechanisms of AD progression and therapeutic approaches are described.
The paradigm of cell biology knowledge and fluorine biochemistry such as, organofluorine inhibitors of amyloid fibrilogenesis, is highlighted.
Export Options
About this article
Cite this article as:
Gomes Barbara, Loureiro A. Joana, Coelho A.N. Manuel and do Carmo Pereira Maria, The Potential Effect of Fluorinated Compounds in the Treatment of Alzheimer’s Disease, Current Pharmaceutical Design 2015; 21 (39) . https://dx.doi.org/10.2174/1381612821666150130120358
DOI https://dx.doi.org/10.2174/1381612821666150130120358 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial: View of Excellent ROAD from the CAR
Current Alzheimer Research Accurate and Unbiased Quantitation of Amyloid-β Fluorescence Images Using ImageSURF
Current Alzheimer Research Blood Pressure and Cognitive Impairment in the Elderly
Current Hypertension Reviews Disrupted Structural Brain Network in AD and aMCI: A Finding of Long Fiber Degeneration
Current Alzheimer Research Prevalence of Analgesic Use and Pain in People with and without Dementia or Cognitive Impairment in Aged Care Facilities: A Systematic Review and Meta-Analysis
Current Clinical Pharmacology Peroxisome Proliferator-Activated Receptor (PPAR) in Metabolic Syndrome and Type 2 Diabetes Mellitus
Current Diabetes Reviews Development and Potential Utility of Dual and Triple NK Receptor Antagonists
Current Topics in Medicinal Chemistry Synaptic Plasticity, Dementia and Alzheimer Disease
CNS & Neurological Disorders - Drug Targets Tuberculostatic Drugs Targeting Infections of the Central Nervous System
Anti-Infective Agents Role of Nut Consumption in the Management of Cognitive Decline - A Mini-Review
Current Alzheimer Research Beta-blockers in the Perioperative Period: Are there Indications other than Prevention of Cardiac Ischemia?
Current Drug Targets Humanized Mouse Models of HIV-1 Latency
Current HIV Research Type 2 Diabetes Mellitus and Invokana: An FDA Approved Drug
Current Diabetes Reviews The Intracellular Domain of Amyloid Precursor Protein is a Potential Therapeutic Target in Alzheimer’s Disease
Current Drug Discovery Technologies Abnormalities of Peptide Metabolism in Alzheimer Disease
Current Neurovascular Research Pathophysiology of Blood-Brain Barrier in Brain Injury in Cold and Hot Environments: Novel Drug Targets for Neuroprotection
CNS & Neurological Disorders - Drug Targets Evidence on the New Drug Lumateperone (ITI-007) for Psychiatric and Neurological Disorders
CNS & Neurological Disorders - Drug Targets Ideational Fluency in Patients with Rheumatoid Arthritis
Current Rheumatology Reviews Novel Iodinated Hydrazide-hydrazones and their Analogues as Acetyl- and Butyrylcholinesterase Inhibitors
Current Topics in Medicinal Chemistry Peripheral Arterial Disease in Persons with Diabetic Foot Ulceration: a Current Comprehensive Overview
Current Diabetes Reviews